NO20074052L - Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere - Google Patents

Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Info

Publication number
NO20074052L
NO20074052L NO20074052A NO20074052A NO20074052L NO 20074052 L NO20074052 L NO 20074052L NO 20074052 A NO20074052 A NO 20074052A NO 20074052 A NO20074052 A NO 20074052A NO 20074052 L NO20074052 L NO 20074052L
Authority
NO
Norway
Prior art keywords
processes
preparing pyrazole
pyrimidine
pyrimidine ethers
ethers
Prior art date
Application number
NO20074052A
Other languages
English (en)
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20074052L publication Critical patent/NO20074052L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter for fremstilling av pyrazolo[3,4-d]-pyrimidineter-forbindelser som er modulatorer av glukosemetabolisme og derfor anvendelige ved behandling av metabolittiske forstyrrelser slik som diabetes og fedme.
NO20074052A 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere NO20074052L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13
PCT/US2006/001020 WO2006076455A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

Publications (1)

Publication Number Publication Date
NO20074052L true NO20074052L (no) 2007-09-12

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074052A NO20074052L (no) 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Country Status (22)

Country Link
US (1) US7425630B2 (no)
EP (1) EP1838713A2 (no)
JP (1) JP2008526975A (no)
KR (1) KR20070114126A (no)
CN (1) CN101142216A (no)
AR (1) AR052557A1 (no)
AU (1) AU2006204940A1 (no)
BR (1) BRPI0606115A2 (no)
CA (1) CA2593345A1 (no)
CR (1) CR9224A (no)
DO (1) DOP2006000009A (no)
EA (1) EA013968B1 (no)
GT (1) GT200600011A (no)
HN (1) HN2006001493A (no)
IL (1) IL184365A0 (no)
MX (1) MX2007008381A (no)
NO (1) NO20074052L (no)
PA (1) PA8659701A1 (no)
PE (1) PE20061118A1 (no)
TW (1) TW200637865A (no)
WO (1) WO2006076455A2 (no)
ZA (1) ZA200705279B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
RS20060018A (sr) * 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2011000664A (es) * 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
JP6567276B2 (ja) 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
CA2969594A1 (en) * 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Pde2 inhibiting organic compounds
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用ｐｗｍ制御装置
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2022268935A2 (en) * 2021-06-23 2022-12-29 F. Hoffmann-La Roche Ag Novel process

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003174A1 (fr) 1980-04-28 1981-11-12 Teijin Ltd Derives de thiazolo (3,2-a) pyrimidine, leur procede de preparation, et medicaments les contenant
EP0053678A1 (de) * 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) * 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
RS20060018A (sr) * 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ZA200705279B (en) 2008-11-26
BRPI0606115A2 (pt) 2009-06-02
AU2006204940A1 (en) 2006-07-20
TW200637865A (en) 2006-11-01
AR052557A1 (es) 2007-03-21
DOP2006000009A (es) 2006-08-15
US20060154940A1 (en) 2006-07-13
KR20070114126A (ko) 2007-11-29
CA2593345A1 (en) 2006-07-20
US7425630B2 (en) 2008-09-16
EP1838713A2 (en) 2007-10-03
PA8659701A1 (es) 2006-09-08
MX2007008381A (es) 2007-09-07
WO2006076455A2 (en) 2006-07-20
IL184365A0 (en) 2007-10-31
GT200600011A (es) 2006-08-10
EA013968B1 (ru) 2010-08-30
WO2006076455A3 (en) 2006-12-07
HN2006001493A (es) 2010-08-19
WO2006076455A8 (en) 2006-11-02
JP2008526975A (ja) 2008-07-24
CR9224A (es) 2007-10-23
CN101142216A (zh) 2008-03-12
EA200701500A1 (ru) 2007-12-28
PE20061118A1 (es) 2006-10-13

Similar Documents

Publication Publication Date Title
NO20074052L (no) Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
MX2007007174A (es) Derivados de cicloalquilamina.
MY148521A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
MY157911A (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
TW200610528A (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2007109211A8 (en) 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
TW200637844A (en) Processes for preparing aromatic ethers
NO20074872L (no) Pyrazoler
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
CY1108736T1 (el) Φαινυλ-και πυριδυλπιπεριδινο-παραγωγα ως ρυθμιστες μεταβολισμου γλυκοζης
TW200745121A (en) Chemical compound
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
UA87026C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[3, 4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
WO2006113237A3 (en) Cd39l3 and its role in diabetes
NZ593021A (en) Method of preparing deoxyribofuranose compounds
WO2007009704A3 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application